{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-023794","form_type":"8-K","ticker":"LQDA","cik":"0001819576","company_name":"Liquidia Corp","filed_at":"2026-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.328634+00:00","generated_at":"2026-05-15T19:49:53.763720+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Liquidia posts Q4 net income $14.6M; YUTREPIA sales $90.1M in Q4, $148.3M FY2025","bullets":["Q4 net income $14.6M, positive non-GAAP adjusted EBITDA $27.3M; FY net loss $68.9M vs $128.3M in 2024.","YUTREPIA net product sales $148.3M in FY2025 ($90.1M Q4) since launch in June 2025; no product revenue in 2024.","Cash and equivalents $190.7M at Dec 31, 2025, up from $176.5M at Dec 31, 2024.","Over 3,600 prescriptions and 2,900 patients started since launch; prescribers ~860, 25% have referred 5+ patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-023794","json":"https://secwatch.observer/filing/0001104659-26-023794.json","markdown":"https://secwatch.observer/filing/0001104659-26-023794.md","text":"https://secwatch.observer/filing/0001104659-26-023794.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819576/000110465926023794/0001104659-26-023794-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819576/000110465926023794/tm267579d3_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T19:49:53.763720+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}